Costanza Vignoli -

Due to the severe impact of COVID-19 pandemic, the European Medicines Regulatory Network has agreed to extend the deadline to complete and submit the outcome of step 1, risk evaluation of all human medicines containing chemically synthesized active substances for the presence of Nitrosamines, which was foreseen for 26 March 2020, according to the “Information on nitrosamines for marketing authorization holders”. The deadline has been shifted to 1 October 2020 and marketing authorization holders are encouraged to provide the outcomes before this date, following the same procedure.

Comments are closed for this post.